Rioprostil: a clinical experience in gastric ulcer treatment.
The efficacy and tolerability of the prostaglandin E1 derivative rioprostil (Bay o 6893) was studied in a randomized, double-blind, placebo-controlled trial in 40 patients affected by acute gastric ulcer. At the end of the eight weeks period ulcer healing was achieved in 85% of the rioprostil-treated patients and in 60% of the placebo-treated ones (p less than 0.05). Rioprostil produced a significant reduction of pain and also improved the clinical status. This positive outcome was noted both in smokers and in non-smoking patients, while only this last group improved during the placebo treatment.
Mascio
G
G
Division of Medicine, S. Maria della Pietà Hospital, Nola, Italy.
Guida
L
L
Mascio
M V
MV
Maggiolo
F
F
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D016630:Rioprostil; D013276:Stomach Ulcer / Q000188:drug therapy*
D011458:Prostaglandins E; D016630:Rioprostil